PT-141 — Vendor Pricing & Purity Guide
Research Overview
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist, FDA-approved in 2019 under the brand name Vyleesi for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the only FDA-approved peptide specifically indicated for sexual dysfunction, and the first medication of its kind to work through the central nervous system rather than the vascular system.
PT-141 was derived from Melanotan II (MT-II), which itself was developed from the natural hormone alpha-melanocyte-stimulating hormone (α-MSH). During Melanotan II research, the sexual arousal side effect was so pronounced that researchers isolated and optimized this activity into PT-141. The peptide works by activating melanocortin-4 receptors (MC4R) in the hypothalamus, which modulate the neural pathways involved in sexual arousal and desire.
Unlike phosphodiesterase inhibitors (Viagra, Cialis) which work on blood flow, PT-141 acts centrally on brain pathways that control sexual desire itself. This makes it effective in cases where vascular medications fail, and it works in both male and female subjects. It is one of the few peptides with full FDA approval and a clear clinical pathway.
Key Research Findings
- •FDA-approved in 2019 (as Vyleesi) for hypoactive sexual desire disorder in premenopausal women
- •Demonstrated statistically significant increases in sexual desire and decreases in distress in Phase III RECONNECT trials
- •Produced erectile responses in men with psychogenic erectile dysfunction unresponsive to PDE5 inhibitors in clinical studies
- •Works through CNS melanocortin pathways rather than vascular mechanisms, representing a novel mechanism for sexual dysfunction
- •Effective in both male and female subjects — one of few compounds with cross-sex efficacy for sexual dysfunction
- •Derived from Melanotan II with optimized selectivity for MC4R over MC1R (reduced tanning/pigmentation effects)
Research Dosage Protocols
PT-141 (Bremelanotide) is FDA-approved as Vyleesi, administered as a 1.75 mg subcutaneous injection approximately 45 minutes before anticipated sexual activity. The FDA label recommends no more than one dose per 24 hours and no more than 8 doses per month.
For research use, PT-141 is available as lyophilized powder requiring reconstitution with bacteriostatic water. Research protocols have studied doses ranging from 0.5 mg to 10 mg subcutaneously, with 1-2 mg being the most common research dose.
Key research considerations: PT-141 can cause transient nausea (40% in clinical trials), facial flushing, and headache. It can also transiently increase blood pressure. These effects are dose-dependent and typically resolve within hours.
For research reference only. Not medical advice. Not for human consumption.
Published Research (2 studies)
- [1]Bremelanotide for the treatment of HSDD in premenopausal women (RECONNECT)— Kingsberg et al., 2019PMID: 31474363
- [2]
Links go to PubMed (NIH National Library of Medicine). PeptideVerdict is not affiliated with these studies.
Price Comparison (18 products from 13 vendors)
| Vendor | Price | Stock |
|---|---|---|
| Polaris Peptides | $50.00 $3.33/mg 15mg lyophilized | Out |
| Triumphant Labs | $34.00 $3.40/mg 10mg | In Stock |
| Peptide Crafters | $35.00 $3.50/mg 10mg lyophilized | In Stock |
| Polaris Peptides | $40.00 $4.00/mg 10mg lyophilized | In Stock |
| Core Peptides | $43.00 $4.30/mg 10mg vial | In Stock |
| Biotech Peptides | $45.00 $4.50/mg 10mg vial | In Stock |
| Simple Peptide | $45.00 $4.50/mg 10mg lyophilized | In Stock |
| Paradigm Peptides | $45.00 $4.50/mg 10mg lyophilized | In Stock |
| Swiss Chems | $49.99 $5.00/mg 10mg vial | In Stock |
| Peptide Sciences | $55.00 $5.50/mg 10mg lyophilized | In Stock |
| Peptide Partners | $84.00 $8.40/mg 10mg | In Stock |
| BioLongevity Labs | $47.97 $9.59/mg 5mg vial | In Stock |
| Triumphant Labs | $289.00 $28.90/mg 10mg | In Stock |
| Peptide Sciences | $140.00 $46.67/mg 3mg lyophilized | In Stock |
| BioLongevity Labs | $199.97 $199.97/mg 1mg vial | In Stock |
| Soma Chems | $49.99 spray | In Stock |
| Soma Chems | $49.99 vial | In Stock |
| Skye Peptides | $44.00 lyophilized | In Stock |
Frequently Asked Questions
What is PT-141?
PT-141 (Bremelanotide) is an FDA-approved peptide that enhances sexual desire by activating melanocortin-4 receptors in the brain. Unlike Viagra or Cialis, it works on desire pathways in the CNS rather than blood flow.
How is PT-141 different from Melanotan II?
PT-141 was derived from Melanotan II but optimized for MC4R (sexual arousal) over MC1R (skin pigmentation). PT-141 produces minimal tanning effects compared to MT-II, but also lacks MT-II's appetite-suppressing properties.
Does PT-141 work for men?
Clinical studies have demonstrated efficacy in men with erectile dysfunction, including those who did not respond to PDE5 inhibitors (Viagra/Cialis). However, the FDA approval (Vyleesi) is currently only for premenopausal women with HSDD.
Where can I buy PT-141 for research?
PT-141 is available from research peptide vendors as lyophilized powder. Compare pricing in the table above.